The microplate is coated with recombinant antigens of P. falciparum and P. vivax. P. ovale and P. malaria are also detected due to the antigenic similarity between the different Plasmodium species.

德國Nova瘧疾檢測試劑盒

瘧疾是一種危及生命的疾病,這是由原生動物引起的瘧原蟲spp。傳播是由瘧蚊傳播,但可以通過輸血也發生。人類可以通過四個不同種類的瘧原蟲感染間日瘧原蟲、惡性瘧原蟲,p .那三日瘧原蟲。

感染惡性瘧原蟲可以是致命的。惡性瘧原蟲和間日瘧原蟲是zui常見的類型。該病主要發生在熱帶和亞熱帶地區。

瘧疾感染誘發特定抗體的生產。一般發生后幾天內可以檢測到血液中的寄生蟲。特定抗體的濃度成正比,感染的強度和持續時間。抗體的檢測比直接檢測更敏感的病原體和獨立地位的感染。*在人類感染的特定抗體水平下降后快速恢復。??比之下抗體水平下降緩慢(在2 ?3年)重新感染的人進入非流行地區。

NovaLisa嗎?瘧疾抗體試驗是一種快速、敏感的酶免疫分析法檢測特定的免疫球蛋白和IgM抗體瘧原蟲。

微型板塊上涂了一層重組抗原的惡性瘧原蟲和間日瘧原蟲。p .那和p .瘧疾也發現由于抗原不同瘧原蟲物種之間的相似性。

硬幣的瘧原蟲	培養時間	類型的瘧疾	發燒的攻擊
惡性瘧原蟲	7-30天(90%) 長(10%)	瘧疾熱帶	不*的
三日瘧原蟲	16-50天	瘧疾Quartana	72小時
p .那	12 - 18天(90%) 長(10%)	瘧疾Tertiana	48小時
間日瘧原蟲	12 - 180天(90%) 長(10%)	瘧疾Tertiana	48小時

感染的診斷則需要通過:

顯微鏡:直接探測和識別病原體是可能的,但不確定

血清學:特定抗體基于ELISA-technique的決心

NovaLisaTM瘧疾ELISA:

NovaLisaTM瘧疾ELISA用于抗體的定性測定瘧原蟲在人類血清或血漿(檸檬酸)。

主要的試驗

定性immunoenzymatic瘧原蟲抗體的確定是基于ELISA(酶聯免疫吸附試驗)技術。

微量滴定板井重新板與瘧原蟲抗原結合相應抗體的標本。洗井后刪除所有的樣品材料hoseradish過氧化物酶(合)貼上人類免疫球蛋白和IgM共軛。這種共軛結合捕獲Plasmodium-specific抗體。

免疫complecx結合共軛形成可視化通過添加Tetramethylbenzidine(*)襯底,使一個藍色的反應產物。這個產品的強度成正比的Plasmodium-specific標本中的抗體。硫酸添加到停止反應。這產生一個黃色端點的顏色。吸光度在450 nm讀取使用ELISA microwell板讀者。

重組抗原:

重組CSP和MSP1蛋白質從間日瘧原蟲和惡性瘧原蟲

具體的性能特征:

Intraassay			Interassay			靈敏度	特異性	協議
n	意思是(E)	CV %	n	意思是(南大)	CV %	95.9% (163/170)	97.5% (276/283)	96.9% (439/453)
22	1.61	2.76	24	33.6	3.16
22	1.89	3.90	24	30.46	4.76
22	0.20	5.52	24	2.54	10.28

訂單信息:

ELISA	的數量決定	產品編號
瘧疾	96年	JL11601

【公司名稱】 廣州健侖生物科技有限公司
【】   
【】
【電子郵件】 Service@jianlun.com
【騰訊 】 712628584 712628583
【公司】 www.jianlun。。ｃｏｍ
【公司地址】 廣州市清華科技園創新基地番禺石樓鎮創啟路63號二期2幢首層

 

 

Malaria

Malaria is a life-threatening disease, which is caused by the protozoon Plasmodium spp. The transmission is mediated by the Anopheles mosquito, but can occur via blood transfusion also. Humans can be infected by four different species of Plasmodium: P. falciparum, P. vivax, P. ovale and P. malariae.

Infections with P. falciparum can be deadly. P. falciparum and P. vivax are the most common types. The disease occurs mainly in tropical and subtropical areas.

The Malaria infection induces the production of specific antibodies. In general they can be detected within some days after the occurrence of the parasites in the blood. The concentration of the specific antibodies is proportional to the intensity and duration of infection. The detection of antibodies is more sensitive than the direct detection of the pathogen and independent of the status of the infection. In humans who are infected for the first time the level of the specific antibodies decreases fast after recuperation. In contrast the antibody level decreases slowly (within 2 ? 3 years) in re-infected persons who move into non-endemic areas.

The NovaLisa? Malaria antibody assay is a fast and sensitive enzyme immunoassay for the detection of specific IgG and IgM antibodies against Plasmodium spp.

The microplate is coated with recombinant antigens of P. falciparum and P. vivax. P. ovale and P. malaria are also detected due to the antigenic similarity between the different Plasmodium species.

Specie of Plasmodium	Incubation Time	Type of Malaria	Fever Attack
P. falciparum	7-30 days (90%) Longer (10%)	Malaria Tropical	Inconsistent
P. malariae	16-50 days	Malaria Quartana	72 hours
P. ovale	12-18 days (90%) Longer (10%)	Malaria Tertiana	48 hours
P. vivax	12-180 days (90%) Longer (10%)	Malaria Tertiana	48 hours

Infections may be diagnosed by:

Microscopy: Direct detection and indentification of the pathogen is possible but uncertain

Serology: Determination of specific antibodies based on the ELISA-technique

NovaLisa^TM Malaria ELISA:

The NovaLisa^TM Malaria ELISA is intended for the qualitative determination of antibodies against Plasmodium in human serum or plasma (citrate).

Principal of the Assay

The qualitative immunoenzymatic determination of antibodies against Plasmodium is based on the ELISA (Enzyme-linked Immunosorbent Assay) technique.

Microtiter strip wells re pre-coated with Plasmodium antigens to bind corresponding antibodies of the specimen. After washing the wells to remove all unbound sample material hoseradish peroxidase (HRP) labeled anti-human IgG and IgM conjugate are added. This conjugate binds to the capture Plasmodium-specific antibodies.

The immune complecx formed by the bound conjugate is visualized by adding Tetramethylbenzidine (TMB) substrate, which gives a blue reaction product. The intensity of this product is proportional to the amount of Plasmodium-specific antibodies in the specimen. Sulphuric acid is added to stop the reaction. This produces a yellow endpoint color. Absorbance at 450 nm is read using an ELISA microwell plate reader.

Recombinant Antigen:

Recombinant CSP and MSP1 proteins from Plasmodium vivax and Plasmodium falciparum

Specific performance characteristics:

Intraassay			Interassay			Sensitivity	Specificity	Agreement
n	Mean (E)	CV%	n	Mean (NTU)	CV%	95.9% (163/170)	97.5% (276/283)	96.9% (439/453)
22	1.61	2.76	24	33.6	3.16
22	1.89	3.90	24	30.46	4.76
22	0.20	5.52	24	2.54	10.28

Order information:

ELISA	Number of determinations	Product number
Malaria	96	MALA0620